Skip to content
An Initiative of AVAC
Search
Back to Resource Library

AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long- acting injectable cabotegravir for HIV prevention

4 August 2022

AVAC press release announcing a new collaboration focused on pricing, innovative funding mechanisms, tracking regulatory approvals, and ensuring the inclusion of civil society in key planning and decision making to speed access to injectable cabotegravir (CAB) for PrEP. Launched at the 24th International AIDS Conference, this collaboration includes AVAC, the Bill and Melinda Gates Foundation, the Children’s Investment Fund Foundation, MedAccess, Unitaid, and ViiV Healthcare.

Topic(s): Community/Advocacy

Product(s): Cabotegravir, Injectable Prep

Format(s): External Link

Source(s): AVAC

Type: External Link

Visit

Featured Resources

External Link

Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods

This article from Current HIV/AIDS Reports reviews facilitators and barriers to use of injectable cabotegravir (CAB) for PrEP by women in sub-Saharan Africa.
Document

Global Acute HIV Infection Algorithm Job Aids for Providers

This tool can assist providers in assessing acute HIV infection (AHI) in clients using oral PrEP, PrEP ring, and CAB PrEP by offering guidance through three steps: HIV testing, recent exposure to HIV assessment, and AHI assessment. Providers are encouraged to use clinical judgement and defer to national guidance as needed.
Document

Gears of Lenacapavir for PrEP Rollout

This report provides a framework for accelerated and equitable introduction of injectable lenacapavir (LEN) for PrEP, including outlining priority actions for different stakeholder groups.
Document

Daily Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (Spanish)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…
Document

HIV Prevention User Journey Tool

The HIV Prevention Journey Tool was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. The digital tool, which has been optimized for use on mobile devices, can be accessed here.…
External Link

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

This article from the New England Journal of Medicine describes the results of PURPOSE 2, the Phase III clinical trial for injectable lenacapavir for PrEP, carried out amongst gay and bisexual men who have sex with men, trans men, trans women, and gender non binary individuals in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and…
Spreadsheet

2024 Q3 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…
Document

Oral PrEP, PrEP Ring, and CAB PrEP Template Guidelines (English)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and injectable cabotegravir (CAB…
Document

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

Document

CAB PrEP Introduction Situation Analysis – South Africa – 2024

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.